| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b5454abd09f216530c44daae0e81afa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate |
2021-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2001c17cb49cfe79cf0dacae58c64da3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac4093f3e1058bc586c828f9a034bf71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d63692d59edab8daa21cc1c82bd989a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f633d76f7d9c19a10e2787589b7a9495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e165707460153fbf929dd3d065afb1a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20799ba56466a5b74200bc5ee8e8f866 |
| publicationDate |
2021-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202140448-A |
| titleOfInvention |
Fused cyclic imide derivatives, preparation method and medical use thereof |
| abstract |
The present disclosure relates to fused cyclic imide derivatives, preparation method and medical use thereof. Specifically, the present disclosure relates to a novel fused cyclic imide cereblon E3 ubiquitin ligase protein-binding ligand compound represented by the general formula (IM) and a protein degradation targeting chimera (PROTACs) containing the same, as well as their preparation methods and their applications in medicine. The substituents of general formula (IM) are the same as defined in the specification. |
| priorityDate |
2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |